A population‐based time‐series analysis of opioid agonist treatment dispensed during pregnancy
Addiction · 2024
DOI: 10.1111/add.16459 ↗At a glance
Journal article in Addiction, 2024. Written by Rose A Schmidt and 5 co-authors. Institution: Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. Major MEDLINE topics: Methadone, Opioid-Related Disorders, Opiate Substitution Treatment, Pregnancy Complications. Cited 2 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ontario Health Data Platform, Institute for Clinical Evaluative Sciences, Ministry of Health.
Abstract (original language)
Background and aims Identifying effective opioid treatment options during pregnancy is a high priority due to the growing prevalence of opioid use disorder across North America. We assessed the temporal impact of three population‐level interventions on the use of opioid agonist treatment (OAT) during pregnancy in Ontario, Canada.
Design
This was a population‐based time‐series analysis to identify trends in the monthly prevalence of pregnant people dispensed methadone and buprenorphine. The impact of adding buprenorphine/naloxone to the public drug formulary, the release of pregnancy‐specific guidance and the start of the COVID‐19 pandemic were assessed. Setting and participants The study was conducted in Ontario, Canada between 1 July 2013 and 31 March 2022, comprising people who delivered a live or stillbirth in any Ontario hospital during the study period.
Measurements
We identified any prescription for methadone or buprenorphine dispensed between the estimated conception date and delivery date and calculated the monthly prevalence of OAT‐exposed pregnancies among all pregnant people in Ontario.
Findings
Overall, rates of OAT during pregnancy have declined since mid‐2018. Methadone‐exposed pregnancies decreased from 0.46% of all pregnancies in Ontario in 2015 to a low of 0.16% in 2022. In the primary analysis, none of the interventions had a statistically significant impact on overall OAT rates; however, in the stratified analyses, there was a small increase in buprenorphine after the formulary change [0.006%, 95% confidence interval (CI) = 0.0032−0.0081, P < 0.0001] and a decrease in buprenorphine after the release of the 2017 guidelines (−0.005%, 95% CI = −0.0080 to −0.0020, P = 0.001) and the start of the COVID‐19 pandemic (−0.003%, 95% CI = −0.0054 to −0.0006, P = 0.015).
Conclusion
Despite changes in guidance and funding, opioid agonist treatment during pregnancy has been declining in Ontario, Canada since 2018.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- Centre for Addiction and Mental Health (CAMH), Institute for Mental Health Policy Research, Toronto, Canada.
- ICES, Toronto, Canada.
- Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, Canada.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
- Management and Evaluation at the University of Toronto, Institute of Health Policy, Toronto, Ontario, Canada.
ORCID profiles: Rose A Schmidt, Tara Gomes
Funding
- Ontario Health Data Platform
- Institute for Clinical Evaluative Sciences
- Ministry of Health
- Ontario Ministry of Health and Long-Term Care
- Ministry of Health, British Columbia
Cite
APA
Schmidt, R. A., Everett, K., Perez-Brumer, A., Strike, C., Rush, B., & Gomes, T. (2024). A population‐based time‐series analysis of opioid agonist treatment dispensed during pregnancy. Addiction. https://doi.org/10.1111/add.16459
Vancouver
Schmidt RA, Everett K, Perez-Brumer A, Strike C, Rush B, Gomes T. A population‐based time‐series analysis of opioid agonist treatment dispensed during pregnancy. Addiction. 2024. doi:10.1111/add.16459
BibTeX
@article{Schmidt2024,
author = {Schmidt, Rose A and Everett, Karl and Perez-Brumer, Amaya and Strike, Carol and Rush, Brian and Gomes, Tara},
title = {A population‐based time‐series analysis of opioid agonist treatment dispensed during pregnancy},
journal = {Addiction},
year = {2024},
doi = {10.1111/add.16459}
}
EUVIMED